Anti-PD-1 single-chain variable fragments in cancer immunotherapy: from molecular engineering to clinical translation
- 9 July 2026
- journal article
- review article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 96 (1) , 73
Abstract
The programmed death-1 (PD-1) immune checkpoint is a core regulator of T-cell exhaustion and immune evasion in cancer. While PD-1/PD-L1 monoclonal antibodies have changed the landscape of cancer immunotherapy, there are barriers to broader application due to their large size, potential for systemic toxicities, and high production costs. In this review article, we will focus on therapeutic development, functional applications, and translational advances of anti-PD-1 single-chain variable fragments (scFvs). Advances in phage-display libraries, immunization methods, and antibody engineering have helped develop high-affinity scFvs with novel structural and mechanistic properties. Direct functional applications incorporating anti-PD-1 scFvs are bispecific and trispecific constructs, antibody–drug conjugates (ADCs), immunotoxins, nanoparticles, and biological vector carriers that incorporate checkpoint blockade with targeted cytotoxicity or immunostimulation. Engineered immune cells, such as armored CAR-Ts, NK cells, and MSCs, can secrete or display anti-PD-1 scFvs within the tumor to provide localized checkpoint inhibition, enhance effector-cell persistence, and remodel the tumor microenvironment. Oncolytic and non-replicating viral vectors can further confine scFv activity to tumors, coupling checkpoint blockade with oncolysis, cytokine expression, or bispecific T-cell engagers. Early-phase clinical trials are currently studying TILs and CAR-TILs engineered to secrete scFvs and oncolytic HSV-1 encoding multifunctional checkpoint payloads across a variety of solid tumors. Taken together, anti-PD-1 scFvs represent a modular platform for localized checkpoint inhibition and potentially improved cost-effectiveness compared with systemic antibodies. Future work should prioritize rational combination strategies and well-designed clinical trials that integrate anti-PD-1 scFv platforms with other immunotherapies and standard treatments to maximize clinical benefit. Graphical abstractKeywords
Funding Information
- Deanship of Scientific Research, King Khalid University (RGP.02/304/46)
This publication has 104 references indexed in Scilit:
- Intestinal probiotics E. coli Nissle 1917 as a targeted vehicle for delivery of p53 and Tum-5 to solid tumors for cancer therapyJournal of Biological Engineering, 2019
- Efficient development and expression of scFv recombinant proteins against PD-L1 surface domain and potency in cancer therapyCytotechnology, 2019
- Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cellsJournal of Hematology & Oncology, 2019
- PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor modelsOncotarget, 2019
- A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancerInvestigational New Drugs, 2018
- Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivoNature Biotechnology, 2018
- Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodiesmAbs, 2018
- Rare, high-affinity mouse anti-PD-1 antibodies that function in checkpoint blockade, discovered using microfluidics and molecular genomicsmAbs, 2017
- Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibitionOncoImmunology, 2016
- Soluble production of a biologically active single-chain antibody against murine PD-L1 in Escherichia coliProtein Expression and Purification, 2014